Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma

Blood

Volumn 109, Issue 2, 2007, Pages 486-491

  Schot, Bart W ^a   Zijlstra, Josée M ^b   Sluiter, Wim J ^a   Van Imhoff, Gustaaf W ^a   Pruim, Jan ^a   Vaalburg, Willem ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EVALUATION; FEMALE; HODGKIN DISEASE; HUMAN; IMAGING; LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; SCORING SYSTEM; UNIVARIATE ANALYSIS;

EID: 33846213431     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-006957     Document Type: Article

References (22)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Brice P, Bouabedallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry, societé francaise de Greffe de Moelle. Bone Marrow Transplant. 1997;20:21-26.
3. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53-59.
4. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 2002;16:260-267.
5. Schot B, van Imhoff G, Pruim J, et al. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol. 2003;123:282-287.
6. The international Non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
7. Hamlin P, Zelenetz A, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989-1996.
8. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2002;20:221-230.
9. Schot B, Pruim J, van Imhoff G, et al. The role of serial pre-transplantation PET in predicting progressive disease in relapsed lymphoma. Haemat J. 2006;91:490-495.
10. Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the HOVON 22 study. Br J Haematol. 2001;114:319-326.
11. Cheson B, Horning S, Coiffier B, et al. Report of an International Workshop to standardize response criteria for Non-Hodgkin's Lymphomas. J Clin Oncol. 1999;17:1244-1253.
12. Chopra R, Linch D, McMillan A, et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol. 1992;81:197-202.
13. Mikhaeel N, Hutchings M, Fields P, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free survival in high-grade non-Hodgkin's lymphoma. Ann Oncol. 2005;16:1514-1523.
14. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
15. Bierman P, Lynch J, Bociek R, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopietic stem cell transplantation. Ann Oncol. 2002;13:1370-1377.
16. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Bone Marrow Transplant. 1997;20:21-26.
17. Horning S, Chao N, Negrin R, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801-813.
18. Hahn T, Benekli M, Wong C, et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant. 2005;35:557-566.
19. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264-3269.
20. 18F]fluoro-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
21. Jerusalem G, Bequin Y, Fassotte M, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613-618.
22. Juweid M, Wiseman G, Vose J, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;21:1-10.